Lexicon to present Phase 3 trial design for sotagliflozin in HCM

Lexicon Pharmaceuticals will unveil study design details of SONATA-HCM, the company’s Phase 3 clinical trial of sotagliflozin as a potential new treatment for adults with hypertrophic cardiomyopathy, at the virtual Hypertrophic Cardiomyopathy Medical Society 2024 Scientific Sessions. Lexicon plans to conduct the multinational study at 130 sites in 20 countries and enroll adults aged 18 years or older diagnosed with symptomatic HCM, either obstructive or non-obstructive. Initial study sites have been activated and patient randomization is underway. Details for the presentation on “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy” is as follows: HCMS – a moderated poster presentation, Friday, September 27, 2:00-2:30p.m. ET, presented by Carolyn Y. Ho, M.D., Cardiology, Brigham and Women’s Hospital, Boston, MA